{"id":37087,"date":"2025-07-10T15:28:00","date_gmt":"2025-07-10T07:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=37087"},"modified":"2025-07-10T15:28:01","modified_gmt":"2025-07-10T07:28:01","slug":"eli-lillys-kisunla-donanemab-receives-fda-label-update-with-new-dosing-schedule-for-alzheimers-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37087","title":{"rendered":"Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment"},"content":{"rendered":"\n

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY<\/a>) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.<\/p>\n\n\n\n

Approval Details<\/strong>
The revised dosing regimen replaces the original schedule of 700 mg for the first three months, followed by 1400 mg monthly. The new titration approach begins with a gradual dose escalation: 350 mg in Month 1, 700 mg in Month 2, 1050 mg in Month 3, and then 1400 mg monthly thereafter. This modification aims to reduce the risk of amyloid-related imaging abnormalities with edema\/effusion (ARIA-E), a known side effect associated with amyloid-targeting therapies.<\/p>\n\n\n\n

Clinical Evidence from TRAILBLAZER-ALZ 6 Study<\/strong>
The updated dosing schedule was supported by data from the TRAILBLAZER-ALZ 6 study, which demonstrated that the new regimen significantly reduced the incidence of ARIA-E at both 24 and 52 weeks compared to the original dosing schedule. Importantly, this reduction in safety risks did not compromise therapeutic efficacy, reinforcing Kisunla’s potential as a safer and effective treatment option for early-stage Alzheimer’s disease.<\/p>\n\n\n\n

Donanemab’s Mechanism of Action<\/strong>
Kisunla (donanemab) is a monthly monoclonal antibody designed to target amyloid plaques in the brain, which are a hallmark of Alzheimer’s disease. By binding to aggregated amyloid-beta proteins, donanemab facilitates their removal from the brain, potentially slowing disease progression and improving cognitive outcomes for patients with early symptomatic AD.<\/p>\n\n\n\n

Significance of the Label Update<\/strong>
The FDA’s approval of the updated dosing schedule represents a significant step forward in optimizing Kisunla’s safety profile while maintaining its therapeutic benefits. This development underscores Eli Lilly’s commitment to advancing innovative treatments for Alzheimer’s disease and improving outcomes for patients with early-stage symptoms.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food…<\/p>\n","protected":false},"author":1,"featured_media":37088,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,15],"class_list":["post-37087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-product-approvals"],"yoast_head":"\nEli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37087\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37087\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T07:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T07:28:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment\",\"datePublished\":\"2025-07-10T07:28:00+00:00\",\"dateModified\":\"2025-07-10T07:28:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087\"},\"wordCount\":330,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1009.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37087#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37087\",\"name\":\"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1009.webp\",\"datePublished\":\"2025-07-10T07:28:00+00:00\",\"dateModified\":\"2025-07-10T07:28:01+00:00\",\"description\":\"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37087\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1009.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1009.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37087#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37087","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment","og_description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.","og_url":"https:\/\/flcube.com\/?p=37087","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-10T07:28:00+00:00","article_modified_time":"2025-07-10T07:28:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37087#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37087"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment","datePublished":"2025-07-10T07:28:00+00:00","dateModified":"2025-07-10T07:28:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37087"},"wordCount":330,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37087#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","keywords":["Eli Lilly","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37087#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37087","url":"https:\/\/flcube.com\/?p=37087","name":"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37087#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37087#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","datePublished":"2025-07-10T07:28:00+00:00","dateModified":"2025-07-10T07:28:01+00:00","description":"US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food and Drug Administration (FDA) has approved a label update for its monthly amyloid-targeting therapy, Kisunla (donanemab). The updated labeling includes a new recommended titration dosing schedule designed to enhance safety and efficacy for adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) or mild dementia-stage AD.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37087#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37087"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37087#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","width":1080,"height":608,"caption":"Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37087#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1009.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37087"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37087\/revisions"}],"predecessor-version":[{"id":37089,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37087\/revisions\/37089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37088"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}